Literature DB >> 22084528

Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries.

D Scott LaMontagne1, Sandhya Barge, Nga Thi Le, Emmanuel Mugisha, Mary E Penny, Sanjay Gandhi, Amynah Janmohamed, Edward Kumakech, N Rocio Mosqueira, Nghi Quy Nguyen, Proma Paul, Yuxiao Tang, Tran Hung Minh, Bella Patel Uttekar, Aisha O Jumaan.   

Abstract

OBJECTIVE: To assess human papillomavirus (HPV) vaccination coverage after demonstration projects conducted in India, Peru, Uganda and Viet Nam by PATH and national governments and to explore the reasons for vaccine acceptance or refusal.
METHODS: Vaccines were delivered through schools or health centres or in combination with other health interventions, and either monthly or through campaigns at fixed time points. Using a two-stage cluster sample design, the authors selected households in demonstration project areas and interviewed over 7000 parents or guardians of adolescent girls to assess coverage and acceptability. They defined full vaccination as the receipt of all three vaccine doses and used an open-ended question to explore acceptability.
FINDINGS: Vaccination coverage in school-based programmes was 82.6% (95% confidence interval, CI: 79.3-85.6) in Peru, 88.9% (95% CI: 84.7-92.4) in 2009 in Uganda and 96.1% (95% CI: 93.0-97.8) in 2009 in Viet Nam. In India, a campaign approach achieved 77.2% (95% CI: 72.4-81.6) to 87.8% (95% CI: 84.3-91.3) coverage, whereas monthly delivery achieved 68.4% (95% CI: 63.4-73.4) to 83.3% (95% CI: 79.3-87.3) coverage. More than two thirds of respondents gave as reasons for accepting the HPV vaccine that: (i) it protects against cervical cancer; (ii) it prevents disease, or (iii) vaccines are good. Refusal was more often driven by programmatic considerations (e.g. school absenteeism) than by opposition to the vaccine.
CONCLUSION: High coverage with HPV vaccine among young adolescent girls was achieved through various delivery strategies in the developing countries studied. Reinforcing positive motivators for vaccine acceptance is likely to facilitate uptake.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22084528      PMCID: PMC3209730          DOI: 10.2471/BLT.11.089862

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  29 in total

1.  New paradigm for prevention of cervical cancer.

Authors:  Andreas M Kaufmann; Achim Schneider
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2006-09-14       Impact factor: 2.435

2.  Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.

Authors:  R E Brown; J G Breugelmans; D Theodoratou; S Bénard
Journal:  Curr Med Res Opin       Date:  2006-04       Impact factor: 2.580

3.  Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru.

Authors:  Mary Penny; Rosario Bartolini; N Rocio Mosqueira; D Scott LaMontagne; Maria Ana Mendoza; Irma Ramos; Jennifer L Winkler; Jose Villafana; Amynah Janmohamed; Aisha O Jumaan
Journal:  Vaccine       Date:  2011-05-24       Impact factor: 3.641

Review 4.  Chapter 24: Psychosocial aspects of vaccine acceptability.

Authors:  Gregory D Zimet; Nicole Liddon; Susan L Rosenthal; Eduardo Lazcano-Ponce; Betania Allen
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

5.  Parental attitudes about sexually transmitted infection vaccination for their adolescent children.

Authors:  Gregory D Zimet; Rose M Mays; Lynne A Sturm; April A Ravert; Susan M Perkins; Beth E Juliar
Journal:  Arch Pediatr Adolesc Med       Date:  2005-02

Review 6.  Prospects and prejudices of human papillomavirus vaccines in India.

Authors:  Bhudev C Das; Showket Hussain; Vilas Nasare; Mausumi Bharadwaj
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

7.  Cervical cancer prevention and the Millennium Development Goals.

Authors:  Scott Wittet; Vivien Tsu
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

8.  Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study.

Authors:  Loretta Brabin; Stephen A Roberts; Rebecca Stretch; David Baxter; Gloria Chambers; Henry Kitchener; Rosemary McCann
Journal:  BMJ       Date:  2008-04-24

9.  Parental acceptance of Human Papillomavirus vaccines.

Authors:  Charlotte H Lenselink; Marloes M J G Gerrits; Willem J G Melchers; Leon F A G Massuger; Dennis van Hamont; Ruud L M Bekkers
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-03-21       Impact factor: 2.435

10.  Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Authors:  Sue J Goldie; Meredith O'Shea; Nicole Gastineau Campos; Mireia Diaz; Steven Sweet; Sun-Young Kim
Journal:  Vaccine       Date:  2008-05-15       Impact factor: 3.641

View more
  91 in total

1.  Human papillomavirus vaccine inaccuracies.

Authors:  Vivien Davis Tsu; D Scott LaMontagne
Journal:  Am J Public Health       Date:  2012-01-19       Impact factor: 9.308

2.  Knowledge and Perceptions of HPV and the HPV Vaccine among Pre-adolescent Girls and Their Guardians in Georgetown, Guyana.

Authors:  E Tyrell; K Ramsammy-Boyce
Journal:  West Indian Med J       Date:  2015-04-28       Impact factor: 0.171

3.  Public health: Prevention comes of age.

Authors:  Michael Eisenstein
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

4.  Effect of school-based human papillomavirus (hpv) vaccination on adolescent girls' knowledge and acceptability of the HPV vaccine in Ibanda District in Uganda.

Authors:  Andrew Kampikaho Turiho; Elialilia S Okello; Wilson W Muhwezi; Steve Harvey; Pauline Byakika-Kibwika; David Meya; Anne R Katahoire
Journal:  Afr J Reprod Health       Date:  2014-12

5.  Achieving high coverage in Rwanda's national human papillomavirus vaccination programme.

Authors:  Agnes Binagwaho; Claire M Wagner; Maurice Gatera; Corine Karema; Cameron T Nutt; Fidele Ngabo
Journal:  Bull World Health Organ       Date:  2012-05-23       Impact factor: 9.408

6.  Feasibility of delivering HPV vaccine to girls aged 10 to 15 years in Uganda.

Authors:  Emmanuel Mugisha; D Scott LaMontagne; Anne R Katahoire; Daniel Murokora; Edward Kumakech; Rachel Seruyange; Vivien Davis Tsu
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

7.  Human papillomavirus (HPV) awareness and vaccine receptivity among Senegalese adolescents.

Authors:  Philip M Massey; Ruth K Boansi; Jessica D Gipson; Rachel M Adams; Helene Riess; Thierno Dieng; Michael L Prelip; Deborah C Glik
Journal:  Trop Med Int Health       Date:  2016-11-14       Impact factor: 2.622

Review 8.  Making HPV vaccination available to girls everywhere.

Authors:  Austin M Oberlin; Lisa Rahangdale; Lameck Chinula; Nurain M Fuseini; Carla J Chibwesha
Journal:  Int J Gynaecol Obstet       Date:  2018-09-12       Impact factor: 3.561

9.  Structural barriers to screening for and treatment of cervical cancer in Peru.

Authors:  Valerie A Paz-Soldán; Angela M Bayer; Lauren Nussbaum; Lilia Cabrera
Journal:  Reprod Health Matters       Date:  2012-12

Review 10.  Implementation science in cancer prevention and control: a framework for research and programs in low- and middle-income countries.

Authors:  Sudha Sivaram; Michael A Sanchez; Barbara K Rimer; Jonathan M Samet; Russell E Glasgow
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-09-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.